A patient comes in for a preventive gynecology appointment, the clinician collects a cervical sample, and the sample goes to a laboratory. On the claim, which code belongs to the office and which belongs to the lab? Searching for a “Pap smear CPT code” can bring up 88175, 88142, and Q0091 together, even though they describe different work.
That distinction matters. A clinician collecting a specimen is not necessarily performing the laboratory examination. A screening service may follow different billing rules from a diagnostic test. Original Medicare also uses screening-specific HCPCS codes and its own benefit limits. Entering the first plausible code can therefore create a duplicate charge, a bundling edit, or a denial.
Quick answer: CPT 88175 and 88142 are laboratory cervical/vaginal cytology codes differentiated by their preparation and screening methods. Q0091 is a HCPCS Level II code, commonly used to report obtaining, preparing, and conveying a screening Pap specimen when payer rules permit it. For Original Medicare screening cytology, appropriate G-series or P-series HCPCS codes may apply instead of a general CPT laboratory code. The correct selection depends on the service actually furnished, the performing entity, the patient’s circumstances, and current payer instructions. The CMS Screening Pap Tests & Pelvic Exams booklet is a useful primary reference.
Pap Smear Codes at a Glance
| Code | Code set | General use | Who typically reports it |
| 88142 | CPT | Liquid-based cervical or vaginal cytology with manual screening | Performing cytology laboratory |
| 88174 | CPT | Liquid-based cytology with automated screening | Performing cytology laboratory |
| 88175 | CPT | Liquid-based cytology with automated screening and required manual rescreening/review | Performing cytology laboratory |
| 88141 | CPT | Separately supported physician interpretation of cytology | Pathologist or authorized billing entity |
| Q0091 | HCPCS Level II | Collection, preparation, and conveyance of a screening Pap specimen | Eligible collecting clinician or organization |
| G0101 | HCPCS Level II | Medicare screening pelvic examination with clinical breast examination | Eligible clinician or organization |
| G0123 | HCPCS Level II | One Medicare-recognized screening cervical/vaginal cytology method | Performing laboratory |
| G0145 | HCPCS Level II | Medicare screening cytology using automated screening with manual rescreening | Performing laboratory |
| G0476 | HCPCS Level II | Medicare-covered screening high-risk HPV test performed with a Pap test | Performing laboratory |
These are representative codes, not a complete coding crosswalk. The current licensed CPT code set and payer-specific claim instructions control final selection. Similar descriptions do not mean a CPT code and a Medicare screening HCPCS code should both be submitted for the same laboratory service.
What Is the CPT Code for a Pap Smear?
The phrase “Pap smear” describes a clinical screening or diagnostic process, not one uniquely reportable billing service. During a typical visit, one person obtains cervical cells, a laboratory prepares and examines those cells, and a clinician receives the results. Sometimes a pathologist provides additional interpretation. An HPV test may be ordered as well.
The first coding question should therefore be what work is represented by the claim line. If the provider merely collects a sample and sends it to a reference lab, a laboratory code such as 88175 does not describe that office’s work. If a lab processes the sample, the lab’s actual technique—not the ordering clinician’s preferred code—determines the relevant cytology code.
In a routine preventive visit, the office may separately report a screening specimen-collection service only when the program or payer allows it. Medicare has a specific collection code, Q0091. Commercial plans may bundle collection into the preventive visit instead. The MedIntelHub guide to the medical billing workflow explains how charge capture, coding, claim submission, and payment can involve different parties.
Pap test versus Pap specimen collection
A Pap test examines cervical or vaginal cells for abnormalities. Collection is the act of obtaining and forwarding those cells. Neither activity is the same as a complete preventive gynecology examination, a pelvic examination, or a high-risk HPV molecular test.
One patient encounter may generate more than one legitimate claim, but only when each billed line represents a distinct service furnished by the correct billing entity and permitted by the payer. Having several available codes does not authorize submitting all of them.
CPT 88175, 88142, and 88174: What Is the Difference?
These three laboratory codes are often confused because they relate to liquid-based cervical or vaginal cytology. The laboratory workflow supplies the distinction.
CPT 88142: liquid-based preparation with manual screening
Code 88142 generally represents cytology prepared through a liquid-based, thin-layer process and screened manually. The term “manual” refers to examination by qualified laboratory personnel. It does not mean the sample was collected without equipment, nor does it describe the patient’s office appointment.
A laboratory using a different rescreening workflow may need another code. The billing record should agree with the laboratory’s method and documentation, not just with the requisition reading “Pap smear.”
CPT 88174: automated laboratory screening
88174 generally describes liquid-based cytology using automated screening without the additional manual rescreening represented by the next code. Laboratories should confirm the current descriptor and any related instructions in a licensed CPT resource. A coding label such as “ThinPrep” or another product name, by itself, does not prove which screening methodology was performed.
CPT 88175: automated screening with manual rescreening or review
88175 is commonly associated with liquid-based cervical/vaginal cytology that uses automated screening together with specified manual rescreening or review. This is a laboratory cytopathology service. It is not the correct default code for the clinician’s act of swabbing the cervix.
When the lab performs the automated method plus the additional manual component included in this code, 88175 may be appropriate for a payer that recognizes the CPT service. Medicare screening claims may use a corresponding screening-specific HCPCS code when required. Verify the exact methodology, code-set instructions, and payer edits for the date of service.
| Question | 88142 | 88174 | 88175 |
| Liquid-based specimen preparation? | Yes | Yes | Yes |
| Main screening approach | Manual | Automated | Automated |
| Additional manual rescreen/review reflected in code? | Not as the defining component | No | Yes |
| Collection performed in the office included? | No | No | No |
| Automatically appropriate for Medicare preventive screening? | No; check Medicare HCPCS policy | No; check Medicare HCPCS policy | No; check Medicare HCPCS policy |
Other cytology codes exist, including codes for conventional smears and different screening workflows. An isolated diagnosis of “Pap” does not justify mapping every specimen to 88175.
When is CPT 88141 appropriate?
88141 concerns professional physician interpretation of cervical or vaginal cytopathology when separately reportable. It is not an automatic extra charge every time a cytotechnologist notices an abnormality or a pathologist signs a laboratory report. Its use depends on actual physician work, the relevant CPT instructions, and payer edits. Do not add it solely to increase reimbursement, and do not assume it can accompany every Medicare screening HCPCS laboratory line.
HCPCS Q0091: Collecting a Screening Pap Specimen
Q0091 is sometimes called the “Pap smear CPT code,” but that description is technically wrong: Q0091 belongs to HCPCS Level II. CMS identifies it as a screening Pap service for obtaining, preparing, and conveying the cervical or vaginal sample to the laboratory. It does not include the lab’s cytology examination. See the CMS screening Pap guide.
For an eligible Original Medicare screening encounter, the clinician or organization collecting the specimen may report Q0091 when documentation and coverage criteria are met. The laboratory separately reports the applicable test code. The collecting office should not also bill 88175 merely because its staff placed the specimen in a vial.
Commercial insurance is less uniform. Some plans recognize Q0091 on a preventive visit, others bundle the work into an office/preventive service, and some have particular diagnosis or frequency requirements. As American Family Physician’s coding discussion explains, a diagnostic sample collected during evaluation of a symptom is not the same as a screening Q0091 service. Verify contract and plan rules rather than applying the Medicare approach to every claim.
Repeat collection after an unsatisfactory specimen
CMS addresses a limited situation in which an initial screening specimen is unsatisfactory and the laboratory cannot interpret it. For a repeat collection by the same clinician or qualified professional, its booklet instructs reporting Q0091 with modifier 76 when applicable. That is not permission to append modifier 76 to every repeat Pap test or bypass a frequency limit. Record why a second specimen was necessary, and apply current payer requirements.
G0101 vs. Q0091 vs. CPT 99459
These codes refer to different services that may occur during a gynecology visit.
G0101 represents a qualifying Medicare screening pelvic and clinical breast examination. Q0091 represents screening specimen collection and conveyance. Neither code, alone, represents the laboratory analysis of cervical cells. A patient can receive an examination without a Pap test, and a Pap collection is not evidence that every element of G0101 was furnished.
CPT +99459 is an add-on code related to practice expense for performing a pelvic examination with an eligible evaluation and management service. It does not replace G0101 and is not a generic Pap collection code. The Society of Gynecologic Oncology describes its E/M relationship. A Medicare Administrative Contractor’s guidance cautions against separately adding 99459 to the same work represented by Q0091 or G0101 because of bundling/overlap.
| Service performed | Relevant reporting concept | Main caution |
| Collect screening Pap specimen and send to lab | Q0091, when covered | Not a cytology laboratory code |
| Perform qualifying Medicare screening pelvic and clinical breast exam | G0101 | Document the required examination; not equivalent to Q0091 |
| Perform pelvic exam with eligible E/M | +99459, when supported and allowed | Verify add-on rules and edits; do not double-count overlapping work |
| Process and screen the Pap specimen | Applicable lab CPT or screening HCPCS code | Performing laboratory and method determine code |
A combined visit still requires separate consideration of each covered service, the full clinical documentation, and any edits that bar duplicate payment.
Original Medicare Pap Smear Billing Rules in 2026
For Original Medicare Part B, the official preventive benefit is the starting point. It differs from private insurance coverage and from modern clinical screening recommendations. The Medicare coverage page explains the patient’s preventive benefit; CMS’s professional guidance explains which codes and conditions apply to claims.
Medicare screening Pap and pelvic exam frequency
Medicare generally covers screening Pap tests and screening pelvic examinations once every 24 months for eligible, asymptomatic beneficiaries. Under qualifying circumstances, such as documented elevated risk of cervical or vaginal cancer or specified recent abnormal testing in someone of childbearing age, coverage may be available once every 12 months. Medicare’s claims guidance uses minimum elapsed-month calculations; the billing team should not treat “once a year” as an unrestricted calendar-year reset.
The record needs to support the relevant risk category or prior abnormality. A patient’s desire for annual screening, by itself, does not create a Medicare high-risk exception. Verify the most recent test or examination, associated dates, and the Medicare eligibility rules before submission.
Medicare screening cytology: the G-series and P-series codes
CMS lists screening laboratory codes including G0123, G0143, G0144, G0145, G0147, G0148, and P3000, together with codes for certain physician interpretations such as G0124, G0141, and P3001. These identify differences in preparation, screening, and interpretation rather than seven interchangeable billing options.
For example, CMS uses G0123 for one thin-layer cytology workflow screened by a cytotechnologist; G0145 identifies a thin-layer automated method that includes manual rescreening. Laboratory staff must map the actual process to the correct current descriptor. Selecting a CPT code solely because it appears in a generic code search may fail to meet Medicare’s screening claim instructions.
Professional claims require the appropriate HCPCS code, diagnosis code, and place of service. Institutional billing has additional type-of-bill and revenue-code requirements. Payments for screening Pap and HPV laboratory services generally follow the Clinical Laboratory Fee Schedule, while covered screening pelvic examinations use the Physician Fee Schedule; special facility methodologies can apply to RHCs, FQHCs, CAHs, hospitals, and skilled nursing facilities. These distinctions are detailed in the CMS MLN booklet.
Medicare patient cost sharing
When Medicare’s preventive coverage conditions are met and a provider accepts assignment, the patient generally pays nothing for the covered screening Pap lab test, appropriate specimen collection, screening pelvic/clinical breast examination, and qualifying HPV test. A diagnostic evaluation, extra service, noncovered interval, or non-participating provider circumstance can change the amount owed. Eligibility does not extend automatically to every procedure performed at the same appointment.
Medicare HPV screening: G0476 is not the same as 87624
CMS’s Medicare coverage rule for asymptomatic beneficiaries aged 30–65 covers qualifying screening high-risk HPV testing once every five years when performed in conjunction with a Pap test. CMS identified G0476 as the code for that Medicare screening benefit in its July 2026 MLN notice. The agency’s Medicare coverage determination also specifies the screening setting.
The CPT code 87624 may describe high-risk HPV molecular testing in other circumstances, but it is not the substitute for G0476 when billing the screening service governed by Medicare NCD 210.2.1. CMS’s billing article calls for Z11.51 as the primary diagnosis with Z01.411 or Z01.419 as an additional diagnosis for that specified screening HPV service. The diagnosis requirements for other lab tests or commercial insurance may differ.
Pap Smear ICD-10-CM Codes: Match the Reason for Testing
Correct procedure coding is only part of the claim. A Pap test can be performed for routine screening or ordered as part of evaluating an abnormality. The diagnosis code should represent the documented reason for the service and applicable claim instructions.
| ICD-10-CM code | General purpose | Coding caution |
| Z12.4 | Screening for malignant neoplasm of cervix | Not a diagnosis of cervical cancer |
| Z01.419 | Routine gynecological exam without abnormal findings | Reflects the visit documented at the encounter |
| Z01.411 | Routine gynecological exam with abnormal findings | Also code the specific abnormal finding as required |
| Z11.51 | Encounter for HPV screening | Medicare G0476 has additional diagnosis rules |
| Z12.72 | Screening for malignant neoplasm of vagina | Only when this screening is appropriate |
| R87.610 | Atypical squamous cells of undetermined significance on cervical cytologic smear | Used for a documented cytology finding, not prospective routine screening |
An abnormal Pap result arriving days after a routine visit does not mean the clinician should automatically change the original preventive encounter diagnosis to “with abnormal findings.” Review when the finding was documented, why the service was ordered, and the ICD-10-CM and payer rules. Likewise, do not assign a high-risk diagnosis simply to qualify a patient for more frequent screening.
For general background on prevention-related visits, see MedIntelHub’s guide to what an annual physical actually includes. A preventive appointment, a cervical cancer screening, a screening pelvic exam, and a problem-oriented gynecologic evaluation are related but not interchangeable services.
Screening Pap Test vs. Diagnostic Pap Test
Screening evaluates an eligible person without signs or symptoms of the target disease according to an appropriate preventive strategy. Diagnostic testing evaluates a clinical concern, a previous abnormality, or another medically indicated question. The intent must be supported by the order and record, not assigned retroactively to obtain favorable coverage.
A patient who is due for age-appropriate preventive screening may have a screening cytology test. A patient with an abnormal prior cervical result may instead require surveillance or diagnostic evaluation under condition-specific clinical guidance. Another patient reporting postcoital bleeding may need a diagnostic assessment that is broader than a routine Pap. A Pap test alone is not a substitute for evaluating concerning symptoms.
Billing teams should confirm what the clinician ordered and which service the lab performed. Q0091 is a screening collection code, so it should not be used as an all-purpose add-on to specimen collection for diagnostic problems. A separate office E/M may be appropriate only when identifiable medically necessary work and payer rules support it; do not automatically add one because a specimen was collected.
2026 Cervical Screening Guidelines: Why the Clinical Rules Are Changing
A 2026 coding guide must separate clinical best practice from what Medicare’s current screening benefit reimburses. Those are related questions with different authorities and implementation timelines.
In January 2026, the Health Resources and Services Administration updated its women’s preventive-services guidelines. For average-risk individuals ages 21–29, cervical cytology every three years remains the recommended approach. For average-risk ages 30–65, primary high-risk HPV testing is preferred, with Pap cytology and co-testing remaining options in defined circumstances. The update also recognizes appropriately supported patient-collected samples for some primary HPV screening. See the HRSA announcement.
In July 2026, the American College of Obstetricians and Gynecologists issued a qualified endorsement of the updated recommendations. Its statement prefers clinician-collected primary high-risk HPV testing every five years for average-risk ages 30–65, while allowing co-testing every five years under specified circumstances and discussing patient self-collection every three years when appropriate systems are available.
These guidelines do not describe every patient’s situation. A history of significant cervical precancer, immunocompromise, certain exposures, prior treatment, or other higher-risk circumstances may require a different plan. People who have had their cervix removed may have different screening needs depending on their history. A qualified clinician should determine the clinical schedule.
Does the 2026 guideline change automatically change Medicare codes?
No. HRSA states that the new preventive coverage requirements for most affected insurance plans begin January 1, 2027. Original Medicare’s existing coverage determination for screening HPV testing with a Pap test and its current claim-coding guidance should still be checked independently. A future plan-coverage implementation date does not erase the 2026 Medicare G0476 requirements or automatically make Q0091 billable for patient-collected HPV-only screening.
The shift toward primary HPV testing is an operational reason for practices to review clinical order sets, specimen workflows, laboratory interfaces, benefit verification, and payer contracts. It is not evidence that CPT 88175, CPT 88142, and Q0091 were deleted in 2026.
Pap Smear Billing Examples
The examples below illustrate how to reason through a claim. They do not guarantee a particular payer will cover or pay the listed services.
Example 1: preventive visit and outside laboratory
A 28-year-old average-risk patient has an age-appropriate preventive gynecology appointment. The clinician collects a cervical specimen and forwards it to an outside laboratory. The lab examines a liquid-based sample using manual screening.
Coding considerations: The practice reports the appropriately documented preventive visit under the patient’s plan. It asks whether specimen collection is separately recognized, rather than automatically billing Q0091. The performing laboratory evaluates whether 88142 fits its actual technique and payer requirements. The office should not report 88142 simply because it collected the sample.
Example 2: Original Medicare screening with eligible pelvic exam
An eligible Original Medicare beneficiary is due for a covered screening Pap test and also receives a properly documented screening pelvic and clinical breast exam. The office obtains the screening cervical sample and sends it to a laboratory.
Coding considerations: The office evaluates Q0091 for covered collection and G0101 for the separately furnished qualifying screening examination. The laboratory reports the appropriate Medicare screening cytology HCPCS code for its method, potentially G0145 when that method is documented. Coverage frequency, risk/eligibility criteria, diagnoses, and overlapping-service edits must all be checked.
Example 3: HPV testing ordered with Medicare Pap screening
A 62-year-old asymptomatic Medicare beneficiary is eligible for screening high-risk HPV testing with a Pap test and meets the program’s interval and other conditions.
Coding considerations: The performing laboratory evaluates G0476 for the screening HPV service, rather than substituting 87624. CMS’s published billing instructions specify Z11.51 plus Z01.411 or Z01.419 for the covered screening HPV service. The separate Pap cytology is coded according to its actual laboratory method. The provider must not assume that every HPV test, including testing performed alone, falls within this Medicare benefit.
Example 4: symptom-driven evaluation
A patient reports new bleeding after intercourse. The clinician evaluates the complaint and orders testing based on the clinical findings.
Coding considerations: The problem-oriented evaluation is documented separately from routine prevention. The specimen and laboratory codes depend on what testing is ordered and performed; Q0091 should not be reflexively appended as though every collected sample were a screening Pap. Appropriate clinical evaluation takes precedence over choosing a convenient screening diagnosis.
Example 5: sample cannot be interpreted
An eligible screening specimen reaches the lab, but the laboratory states that it was unsatisfactory for interpretation. The clinician later obtains another specimen.
Coding considerations: Determine the reason for repeating the test and the applicable payer requirements. CMS provides specific instructions for repeating a screening collection with Q0091 and modifier 76 when the outlined criteria are met. Do not treat the first unsatisfactory result as automatic permission to rebill every line with the same modifier.
Common Pap Smear Claim Denials and How to Fix Them
A denial may reflect an incorrect code, a frequency limitation, a missing diagnosis relationship, lack of eligibility, or duplicate billing. The remittance advice and the payer’s policy identify which problem actually occurred.
| Claim problem | What to investigate | Sensible next step |
| 88175 billed by collecting office | Who performed laboratory cytology? | Correct billing-entity or service assignment when appropriate |
| Q0091 denied as bundled | Payer’s preventive visit/collection policy | Verify contract; do not use an unsupported modifier |
| Medicare screening test too frequent | Previous paid tests, required interval, risk evidence | Check dates and documented exception before appeal/rebill |
| 87624 used for Medicare screening HPV | NCD 210.2.1 and G0476 instructions | Correct if the service and claim circumstances support it |
| G0101 denied | Whether the qualifying exam and documentation were present | Review medical record and screening benefit requirements |
| HPV screening denied for diagnoses | Specific payer/MAC diagnosis coding requirements | Verify Z11.51 and any required additional diagnosis |
| Duplicate cytology charges | Lab claims, practice charges, related HCPCS/CPT codes | Remove unperformed or redundant services |
Start by reviewing the claim as submitted, the clinical order, laboratory report, insurance eligibility, payer policy for the service date, and explanation of benefits or remittance advice. If a valid service was miscoded, submit the appropriate correction through the payer’s corrected-claim procedure. If the payer made a processing mistake, provide the supporting records through its reconsideration process. Do not automatically appeal an unsupported service.
A repeatable workflow is more useful than a list of denial codes. The MedIntelHub claim-denial prevention and follow-up checklist covers pre-submission validation, payment posting, and denial tracking.
Documentation Checklist for Pap Smear Claims
Before releasing the claim, the clinician’s office and laboratory should be able to answer several basic questions:
- Clinical indication: Was this screening, surveillance, or diagnostic evaluation? Was the reason for ordering the test documented?
- Eligibility and timing: What prior screening dates and risk factors affect the payer’s frequency rules?
- Services furnished: Was a specimen collected, a qualifying pelvic/clinical breast exam performed, a preventive visit completed, or a separate problem addressed?
- Laboratory method: Was the sample conventional or liquid-based? Manual screening, automated screening, and additional rescreening must agree with the laboratory record.
- Performer and billing party: Which organization actually collected the specimen, and which performed the cytology or HPV assay?
- Code and diagnosis: Are CPT/HCPCS lines, ICD-10-CM codes, and any required modifiers linked appropriately?
- Payer and setting: Does the payer recognize a separate collection service? Is the claim professional, facility, RHC, FQHC, or another setting?
- Results and follow-up: Is the result communicated and appropriate follow-up arranged according to the clinician’s medical judgment?
For large OB/GYN practices, electronic order sets should distinguish “screening Pap,” “diagnostic cytology,” and “high-risk HPV testing” instead of mapping all three to a single generic laboratory charge. A periodic audit of charge-capture rules can catch payer-specific changes before they become recurring denials.
Frequently Asked Questions About Pap Smear CPT Codes
1. What is the most common Pap smear CPT code?
88175 is a frequently searched cytology code, but it is not universally appropriate. The performing laboratory must select the code matching its actual preparation and screening method. A specimen-collection claim or Medicare screening test may require a different code.
2. Is 88175 the code for taking the Pap smear in the doctor’s office?
No. It concerns laboratory cervical or vaginal cytology. The office’s collection work may be represented by HCPCS Q0091 when the applicable screening and payer rules allow it.
3. What is the difference between CPT 88175 and 88142?
Both concern liquid-based cytology. In general, 88142 uses manual screening, while 88175 describes automated screening with the specified additional manual rescreening or review. Confirm the exact 2026 code descriptors.
4. Is Q0091 a CPT code or HCPCS code?
Q0091 is HCPCS Level II, not CPT. It identifies screening Pap specimen collection, preparation, and conveyance rather than the cytology laboratory test.
5. Can Q0091 and G0101 be billed together?
They may be separately reportable for distinct, qualifying Medicare screening services furnished during the same encounter, provided both sets of requirements are met. Q0091 does not prove that the pelvic/clinical breast examination required for G0101 occurred.
6. Does Original Medicare pay for Pap smears every year?
Usually, covered Pap screening is every 24 months. Certain documented high-risk situations or qualifying recent abnormal examinations permit a 12-month interval. Verify the minimum time elapsed and the patient’s eligibility.
7. What code does Medicare use for a screening Pap lab test?
Medicare recognizes several screening-specific HCPCS codes, including G0123 and G0145, with selection based on the laboratory method. There is no single Medicare screening cytology code for every specimen.
8. What is G0101 in Pap smear billing?
G0101 identifies a qualifying Medicare screening pelvic and clinical breast examination. It is not a laboratory test and does not replace Q0091.
9. Can CPT 99459 be reported with a Pap smear?
It may be appropriate with an eligible E/M service and separately documented pelvic examination work, but not as an automatic collection add-on. Check CPT add-on requirements, Medicare contractor guidance, payer edits, and possible overlap with G0101 or Q0091.
10. What ICD-10 code is used for Pap smear screening?
Z12.4 identifies cervical cancer screening. A documented routine gynecological examination may use Z01.419 or Z01.411, depending on findings. The correct claim diagnosis follows the clinical purpose and payer requirements.
11. Is the HPV test included in CPT 88175?
No. 88175 describes cytology, not an HPV molecular assay. A separately ordered HPV test must be evaluated under its own coding and coverage requirements.
12. When should Medicare screening HPV be billed with G0476?
For the qualifying screening benefit described in Medicare NCD 210.2.1, generally for an asymptomatic patient age 30–65 receiving HPV screening in conjunction with a Pap test and meeting the five-year limitation. CMS instructs use of G0476 rather than 87624 for that screening benefit.
13. Can a Pap smear be billed during a preventive visit?
A Pap test may occur at a preventive appointment when clinically appropriate. Whether the visit, collection, cytology, and HPV test are each separately payable depends on who provided them, the documented services, and payer-specific bundling and coverage policies.
14. Will a Pap test always be needed at an annual well-woman visit?
No. Screening schedules are based on age, prior tests, medical history, and risk. The 2026 HRSA/ACOG guidance increasingly emphasizes primary high-risk HPV testing for many average-risk patients age 30–65, rather than automatic annual Pap cytology.
15. Did Pap smear CPT codes change in 2026?
The major verified 2026 development is updated cervical cancer screening guidance, not a blanket elimination of 88175, 88142, or Q0091. Current CPT descriptors, Medicare notices, claim edits, and individual payer policies still need review for each date of service.
What Billing Teams Should Remember
The simplest way to avoid Pap smear coding errors is to separate the office encounter, screening specimen collection, laboratory cytology, pelvic examination, and HPV testing before assigning a code. 88175 and 88142 are not interchangeable laboratory labels. Q0091 is a screening collection HCPCS code; G0101 is a different screening exam; and G0476 has specific Medicare HPV screening rules.
Clinical recommendations are changing in 2026, particularly for primary HPV testing in average-risk adults. That does not remove the need to verify Medicare’s existing benefit criteria, the commercial plan’s payment rules, or the actual work documented. Good coding starts with an accurate clinical and laboratory record, not a favored number on an office charge sheet.
Resources
Centers for Medicare & Medicaid Services — Screening Pap Tests & Pelvic Exams
This Medicare Learning Network booklet details covered screening services, laboratory HCPCS codes, specimen collection, pelvic examinations, diagnosis codes, frequency limitations, and claim settings.
Read CMS Screening Pap Tests & Pelvic Exams
Medicare.gov — Cervical and Vaginal Cancer Screenings
A plain-language explanation of Original Medicare screening frequency, eligibility exceptions, and patient cost sharing.
Centers for Medicare & Medicaid Services — HPV Screening National Coverage Determination 210.2.1
Defines Original Medicare’s covered screening HPV benefit and its relationship to the Pap test.
Centers for Medicare & Medicaid Services — Screening HPV Billing and Coding Article
Explains use of G0476 and its required diagnosis coding for the specified Medicare screening HPV benefit.
Health Resources and Services Administration — 2026 Cervical Cancer Screening Update
Announces the updated preventive-services guideline, primary HPV screening preference, patient-collection option, and associated 2027 coverage implementation timeline.
American College of Obstetricians and Gynecologists — Screening for Cervical Cancer (2026)
Offers the society’s qualified endorsement and clinical screening recommendations for average-risk populations, including important qualifications.
Read ACOG’s Committee Statement
Society of Gynecologic Oncology — Pelvic Examination Add-On Code 99459
Describes the distinct practice-expense add-on code and its relationship to qualifying evaluation and management services.
Editorial Guidelines & Medical Disclaimer
This article is intended for healthcare education and medical billing reference. It does not diagnose cervical disease, recommend an individual screening schedule, or replace assessment by a qualified healthcare professional. A Pap test, HPV test, pelvic examination, and diagnostic evaluation serve different purposes. People with symptoms, a prior abnormal result, immune suppression, or other significant risk factors should discuss appropriate screening or follow-up with their healthcare team; symptoms that are concerning or worsening merit medical evaluation.
CPT, HCPCS, ICD-10-CM, Medicare, Medicaid, and commercial-payer requirements can change. A published code does not establish medical necessity, eligibility, separate payment, or coverage. Coding professionals should check the current licensed CPT code set, official HCPCS and ICD-10-CM materials, relevant CMS guidance, and the individual payer’s date-of-service policy before filing claims. Medicare Advantage and Medicaid managed-care plans may have different administrative requirements from Original Medicare. Medication and treatment decisions, where relevant, belong with a licensed clinician. This article draws on CMS, HRSA, ACOG, specialty-society, and related authoritative sources. Learn more about MedIntelHub’s editorial standards.